Herpes Zoster and the Zoster Eye Disease Study (ZEDS)

  • Elisabeth J. CohenEmail author
  • Bennie H. Jeng


Herpes zoster (HZ), including herpes zoster ophthalmicus (HZO), is a very common disease caused by the reactivation of varicella zoster virus (VZV), with serious, potentially vision- and life-threatening complications. Alarmingly, the incidence of HZ is increasing while age at onset is decreasing, but it is preventable by vaccination. When HZ does occur, current recommended treatment reduces eye disease, but does not prevent chronic and/or recurrent eye disease, nor postherpetic neuralgia. New treatment with prolonged suppressive antiviral treatment for HZO is under investigation in a multicenter randomized controlled clinical trial supported by the National Eye Institute to determine whether or not it is effective in reducing complications, including eye disease and/or postherpetic neuralgia.


Herpes zoster Herpes zoster ophthalmicus Varicella zoster virus Zoster Eye Disease Study Zoster vaccine live Recombinant zoster vaccine Herpes zoster vaccination 


  1. 1.
    Lee HL, Yeo M, Choi GH, Lee JY, Kim JS, Shin DI, et al. Clinical characteristics of headache or facial pain prior to the development of acute herpes zoster of the head. ClinNeurolNeurosurg. 2017;152:90–4.Google Scholar
  2. 2.
    Lewis GW. Zoster sine herpete. Br Med J. 1958;2(5093):418–21.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Food and Drug Administration. Zoster Vaccine Live. 2006. Available from:
  4. 4.
    Food and Drug Administration. Zoster Vaccine Recombinant, Adjuvanted. 2017. Available from:
  5. 5.
    Centers for the Disease Control and Prevention. Shingles (Herpes Zoster). Available from:
  6. 6.
    Suaya JA, Chen SY, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1(2):ofu049.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2Suppl):S3–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ghaznawi N, Virdi A, Dayan A, Hammersmith KM, Rapuano CJ, Laibson PR, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology. 2011;118(11):2242–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis. 2010;50(7):1000–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Chan AY, Conrady CD, Ding K, Dvorak JD, Stone DU. Factors associated with age of onset of herpes zoster ophthalmicus. Cornea. 2015;34(5):535–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Davies EC, Pavan-Langston D, Chodosh J. Herpes zoster ophthalmicus: declining age at presentation. Br J Ophthalmol. 2016;100(3):312–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Kawai K, Yawn BP, Wollan P, Harpaz R. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63(2):221–6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gershon AA. Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future? J Infect. 2017;74(Suppl 1):S27–s33.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kawai K, Yawn BP. Risk factors for herpes zoster: asystematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Matthews A, Turkson M, Forbes H, Langan SM, Smeeth L, Bhaskaran K. Statin use and the risk of herpes zoster: a nested case-control study using primary care data from the U.K. Clinical Research Practice Datalink. Br J Dermatol. 2016;175(6):1183–94.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Borkar DS, Tham VM, Esterberg E, Ray KJ, Vinoya AC, Parker JV, et al. Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. Ophthalmology. 2013;120(3):451–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen MH, Wei HT, Su TP, Li CT, Lin WC, Chang WH, et al. Risk of depressive disorder among patients with herpes zoster: a nationwide population-based prospective study. Psychosom Med. 2014;76(4):285–91.CrossRefPubMedGoogle Scholar
  22. 22.
    Hess TM, Lutz LJ, Nauss LA, Lamer TJ. Treatment of acute herpetic neuralgia. A case report and review of the literature. Minn Med. 1990;73(4):37–40.PubMedGoogle Scholar
  23. 23.
    Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88(6):562–70.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hoang-Xuan T, Buchi ER, Herbort CP, Denis J, Frot P, Thenault S, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99(7):1062–70; discussion 70–1.CrossRefPubMedGoogle Scholar
  25. 25.
    Tran KD, Falcone MM, Choi DS, Goldhardt R, Karp CL, Davis JL, et al. Epidemiology of herpes zoster ophthalmicus: recurrence and chronicity. Ophthalmology. 2016;123(7):1469–75.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    He Y, de Melo Franco R, Kron-Gray MM, Musch DC, Soong HK. Outcomes of cataract surgery in eyes with previous herpes zoster ophthalmicus. J Cataract Refract Surg. 2015;41(4):771–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Breuer J, Pacou M, Gautier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology. 2014;83(2):e27–33.CrossRefPubMedGoogle Scholar
  28. 28.
    Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis. 2014;58(11):1497–503.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nagel MA, Gilden D. The relationship between herpes zoster and stroke. CurrNeurolNeurosci Rep. 2015;15(4):16.Google Scholar
  30. 30.
    Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;84(19):1948–55.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Buckingham EM, Foley MA, Grose C, Syed NA, Smith ME, Margolis TP, et al. Identification of herpes zoster-associated temporal arteritis among cases of giant cell arteritis. Am J Ophthalmol. 2018;187:51–60.CrossRefPubMedGoogle Scholar
  32. 32.
    Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMedGoogle Scholar
  34. 34.
    Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a vaccine safety Datalink study. J Intern Med. 2012;271(5):510–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMedGoogle Scholar
  40. 40.
    Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.CrossRefPubMedGoogle Scholar
  41. 41.
    Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148–54.CrossRefPubMedGoogle Scholar
  42. 42.
    Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, et al. Immunogenicity and safety of an Adjuvantedherpes zoster subunit vaccine coadministeredwith seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–61.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Oxman MN, Harbecke R, Koelle DM. Clinical usage of the adjuvantedherpes zoster subunit vaccine (HZ/su): revaccination of recipients of live attenuated zoster vaccine and coadministrationwith a seasonal influenza vaccine. J Infect Dis. 2017;216(11):1329–33.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, et al. Immunogenicity and safety of the HZ/suadjuvantedherpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343–51.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88–93.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum VaccinImmunother. 2017;13(5):1051–8.Google Scholar
  47. 47.
    Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations –United States, 2015. MMWRSurveillSumm(Washington, DC: 2002). 2017;66(11):1–28.Google Scholar
  48. 48.
    Lu PJ, O'Halloran A, Williams WW, Harpaz R. National and state-specific shingles vaccination among adults aged ≥60 years. Am J Prev Med. 2017;52(3):362–72.CrossRefPubMedGoogle Scholar
  49. 49.
    Dommasch ED, Joyce CJ, Mostaghimi A. Trends in Nationwide herpes zoster emergency department utilization from 2006 to 2013. JAMA Dermatol. 2017;153(9):874–81.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555–60.CrossRefPubMedGoogle Scholar
  51. 51.
    Hurley LP, Bridges CB, Harpaz R, Allison MA, ST OL, Crane LA, et al. Physician attitudes toward adult vaccines and other preventive practices, United States, 2012. Public Health Rep (Washington, DC: 1974). 2016;131(2):320–30.CrossRefGoogle Scholar
  52. 52.
    Elkin ZP, Cohen EJ, Goldberg JD, Li X, Castano E, Gillespie C, et al. Improving adherence to national recommendations for zoster vaccination through simple interventions. Eye Contact Lens. 2014;40(4):225–31.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Tsui E, Gillespie C, Perskin M, Zabar S, Wu M, Cohen EJ. Evaluating physician attitudes and practices regarding herpes zoster vaccination. Cornea. 2018;37(8):947–51.CrossRefPubMedGoogle Scholar
  54. 54.
    Ophthalmology AAo. Recommendations for herpes zoster vaccine for patients 50 years and older – 2016. Available from:
  55. 55.
    Le P, Rothberg MB. Cost-effectiveness of the recommendations of the advisory committee on immunization practices for the recombinant adjuvantedzoster subunit vaccine. JAMA Intern Med. 2018;178(9):1277–8.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Harpaz R, Leung J. When zoster hits close to home: impact of personal zoster awareness on zoster vaccine uptake in the U.S. Vaccine. 2017;35(27):3457–60.CrossRefPubMedGoogle Scholar
  57. 57.
    Bonanni P, Bonaccorsi G, Lorini C, Santomauro F, Tiscione E, Boccalini S, et al. Focusing on the implementation of 21st century vaccines for adults. Vaccine. 2018;36(36):5358–65.CrossRefPubMedGoogle Scholar
  58. 58.
    Pavan-Langston D, Yamamoto S, Dunkel EC. Delayed herpes zoster pseudodendrites. Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. ArchOphthalmol (Chicago, Ill: 1960). 1995;113(11):1381–5.CrossRefGoogle Scholar
  59. 59.
    Hu AY, Strauss EC, Holland GN, Chan MF, Yu F, Margolis TP. Late varicella-zoster virus dendriform keratitis in patients with histories of herpes zoster ophthalmicus. Am J Ophthalmol. 2010;149(2):214–20.e3.CrossRefPubMedGoogle Scholar
  60. 60.
    Takase H, Kubono R, Terada Y, Imai A, Fukuda S, Tomita M, et al. Comparison of the ocular characteristics of anterior uveitis caused by herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Jpn J Ophthalmol. 2014;58(6):473–82.CrossRefPubMedGoogle Scholar
  61. 61.
    Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998;339(5):300–6.Google Scholar
  62. 62.
    Lo D, Jeng B, Gilliespie C, Wu M, Cohen E. Current practice patterns and opinions in the management of recent onset or chronic Herpes Zoster Ophthalmicus of Zoster Eye Disease Study investigators. Cornea. 2019;38(1):13–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.NYU School of Medicine, NYU Langone Health, Department of OphthalmologyNew YorkUSA
  2. 2.University of Maryland School of MedicineBaltimoreUSA

Personalised recommendations